Letairis vs Uptravi
Side-by-side cost comparison based on Medicare Part D data
Letairis
Ambrisentan
Manufactured by Gilead
Uptravi
Selexipag
Manufactured by Janssen
Letairis costs 35% less per claim than Uptravi ($8,338.00 vs $12,882.00). A generic version of Letairis is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Letairis | Uptravi |
|---|---|---|
| Avg Cost Per Claim | $8,338.00 | $12,882.00 |
| Total Medicare Spending | $567.0M | $876.0M |
| Total Beneficiaries | 6,800 | 6,800 |
| Total Claims | 68,000 | 68,000 |
| Annual Cost/Patient | $83,382.00 | $128,824.00 |
| Year-over-Year Change | -4.8% | +12.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Gilead | Janssen |
| Condition | Pulmonary Hypertension | Pulmonary Hypertension |
| Generic Name | Ambrisentan | Selexipag |
Letairis vs Uptravi: What the Data Shows
Letairis (Ambrisentan) and Uptravi (Selexipag) are both used to treat pulmonary hypertension. Based on Medicare Part D data, Letairis costs $8,338.00 per claim, which is 35% less than Uptravi at $12,882.00 per claim.
Medicare spent $567.0M on Letairis and $876.0M on Uptravi. In terms of patient reach, Uptravi serves more beneficiaries (6,800 vs 6,800).
Year-over-year spending changed -4.8% for Letairis and +12.6% for Uptravi. Uptravi saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Letairis is cheaper at $8,338.00 per claim, compared to $12,882.00 for Uptravi. That makes Letairis about 35% less expensive per claim based on Medicare Part D data.
Yes, both Letairis and Uptravi are used to treat pulmonary hypertension. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ambrisentan and generic Selexipag can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Letairis covering 6,800 beneficiaries, and $876.0M on Uptravi covering 6,800 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.